Literature DB >> 29036631

ID(H)entifying checkpoint inhibitor candidates among diffuse glioma.

Felix Sahm1, Antje Wick1.   

Abstract

Entities:  

Mesh:

Year:  2017        PMID: 29036631      PMCID: PMC5737517          DOI: 10.1093/neuonc/nox145

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  10 in total

1.  Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas.

Authors:  Jennifer E Kim; Mira A Patel; Antonella Mangraviti; Eileen S Kim; Debebe Theodros; Esteban Velarde; Ann Liu; Eric W Sankey; Ada Tam; Haiying Xu; Dimitrios Mathios; Christopher M Jackson; Sarah Harris-Bookman; Tomas Garzon-Muvdi; Mary Sheu; Allison M Martin; Betty M Tyler; Phuoc T Tran; Xiaobu Ye; Alessandro Olivi; Janis M Taube; Peter C Burger; Charles G Drake; Henry Brem; Drew M Pardoll; Michael Lim
Journal:  Clin Cancer Res       Date:  2016-06-29       Impact factor: 12.531

Review 2.  Neurological sequelae of cancer immunotherapies and targeted therapies.

Authors:  Wolfgang Wick; Anne Hertenstein; Michael Platten
Journal:  Lancet Oncol       Date:  2016-12       Impact factor: 41.316

3.  PD-L1 expression and prognostic impact in glioblastoma.

Authors:  Edjah K Nduom; Jun Wei; Nasser K Yaghi; Neal Huang; Ling-Yuan Kong; Konrad Gabrusiewicz; Xiaoyang Ling; Shouhao Zhou; Cristina Ivan; Jie Qing Chen; Jared K Burks; Greg N Fuller; George A Calin; Charles A Conrad; Caitlin Creasy; Krit Ritthipichai; Laszlo Radvanyi; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2015-08-30       Impact factor: 12.300

Review 4.  Prospects of immune checkpoint modulators in the treatment of glioblastoma.

Authors:  Matthias Preusser; Michael Lim; David A Hafler; David A Reardon; John H Sampson
Journal:  Nat Rev Neurol       Date:  2015-08-11       Impact factor: 42.937

5.  Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.

Authors:  Sarah T Garber; Yuuri Hashimoto; Shiao-Pei Weathers; Joanne Xiu; Zoran Gatalica; Roel G W Verhaak; Shouhao Zhou; Gregory N Fuller; Mustafa Khasraw; John de Groot; Sandeep K Reddy; David Spetzler; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2016-07-01       Impact factor: 12.300

6.  Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.

Authors:  David A Reardon; Prafulla C Gokhale; Sarah R Klein; Keith L Ligon; Scott J Rodig; Shakti H Ramkissoon; Kristen L Jones; Amy Saur Conway; Xiaoyun Liao; Jun Zhou; Patrick Y Wen; Annick D Van Den Abbeele; F Stephen Hodi; Lei Qin; Nancy E Kohl; Arlene H Sharpe; Glenn Dranoff; Gordon J Freeman
Journal:  Cancer Immunol Res       Date:  2015-11-06       Impact factor: 11.151

7.  Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.

Authors:  Eric Bouffet; Valérie Larouche; Brittany B Campbell; Daniele Merico; Richard de Borja; Melyssa Aronson; Carol Durno; Joerg Krueger; Vanja Cabric; Vijay Ramaswamy; Nataliya Zhukova; Gary Mason; Roula Farah; Samina Afzal; Michal Yalon; Gideon Rechavi; Vanan Magimairajan; Michael F Walsh; Shlomi Constantini; Rina Dvir; Ronit Elhasid; Alyssa Reddy; Michael Osborn; Michael Sullivan; Jordan Hansford; Andrew Dodgshun; Nancy Klauber-Demore; Lindsay Peterson; Sunil Patel; Scott Lindhorst; Jeffrey Atkinson; Zane Cohen; Rachel Laframboise; Peter Dirks; Michael Taylor; David Malkin; Steffen Albrecht; Roy W R Dudley; Nada Jabado; Cynthia E Hawkins; Adam Shlien; Uri Tabori
Journal:  J Clin Oncol       Date:  2016-03-21       Impact factor: 44.544

8.  Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.

Authors:  Anna Sophie Berghoff; Barbara Kiesel; Georg Widhalm; Orsolya Rajky; Gerda Ricken; Adelheid Wöhrer; Karin Dieckmann; Martin Filipits; Anita Brandstetter; Michael Weller; Sebastian Kurscheid; Monika E Hegi; Christoph C Zielinski; Christine Marosi; Johannes A Hainfellner; Matthias Preusser; Wolfgang Wick
Journal:  Neuro Oncol       Date:  2014-10-29       Impact factor: 12.300

9.  Correlation of immune phenotype with IDH mutation in diffuse glioma.

Authors:  Anna Sophie Berghoff; Barbara Kiesel; Georg Widhalm; Dorothee Wilhelm; Orsolya Rajky; Sebastian Kurscheid; Philip Kresl; Adelheid Wöhrer; Christine Marosi; Monika E Hegi; Matthias Preusser
Journal:  Neuro Oncol       Date:  2017-10-19       Impact factor: 13.029

10.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.

Authors:  Sevin Turcan; Daniel Rohle; Anuj Goenka; Logan A Walsh; Fang Fang; Emrullah Yilmaz; Carl Campos; Armida W M Fabius; Chao Lu; Patrick S Ward; Craig B Thompson; Andrew Kaufman; Olga Guryanova; Ross Levine; Adriana Heguy; Agnes Viale; Luc G T Morris; Jason T Huse; Ingo K Mellinghoff; Timothy A Chan
Journal:  Nature       Date:  2012-02-15       Impact factor: 69.504

  10 in total
  1 in total

1.  Low-grade glioma harbors few CD8 T cells, which is accompanied by decreased expression of chemo-attractants, not immunogenic antigens.

Authors:  Bas Weenink; Kaspar Draaisma; Han Z Ooi; Johan M Kros; Peter A E Sillevis Smitt; Reno Debets; Pim J French
Journal:  Sci Rep       Date:  2019-10-10       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.